Haematology 2018

Double and Triple Hit…

• 5% of DLBCL patients • Approx. 60% BCL2 , 20% BCL6 and 20% triple hit • Limited data on MYC/BCL6 DHL therapy • R-CHOP is inadequate therapy • Do we need to FISH all DLBCL cases? Low prevalence

OS DHL BC Series

Johnson et al. Blood 2009